Focused On-demand Library for Bardet-Biedl syndrome 10 protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8TAM1

UPID:

BBS10_HUMAN

Alternative names:

Alternative UPACC:

Q8TAM1; Q96CW2; Q9H5D2

Background:

The Bardet-Biedl syndrome 10 protein, encoded by the gene with accession number Q8TAM1, is implicated in a range of critical cellular processes. It functions as a probable molecular chaperone, facilitating protein folding upon ATP hydrolysis. This protein is pivotal in the assembly of the BBSome complex, essential for ciliogenesis and vesicle transport to cilia, and plays a significant role in adipogenic differentiation.

Therapeutic significance:

Given its involvement in Bardet-Biedl syndrome 10, a condition marked by severe pigmentary retinopathy, obesity, polydactyly, and other systemic manifestations, the Bardet-Biedl syndrome 10 protein represents a promising target for therapeutic intervention. Understanding the role of this protein could open doors to potential therapeutic strategies, particularly for tackling the multifaceted symptoms of Bardet-Biedl syndrome.